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Abstract
Introduction: The human papillomavirus (HPV) is the major etiologic agent in the development of cervical
cancer and its natural history of infection is altered in persons infected with the human immunodeficiency virus
(HIV). The prevalence of HPV infection and cervical dysplasia in the HIV sero-positive females in the Bahamas is
not known. Finding out the prevalence would allow for the establishment of protocols to optimize total care of
this population and help prevent morbidity and mortality related to cervical cancer.
Objective: The Objective of this study is to determine the prevalence of high risk HPV genotypes and the
prevalence of cervical dysplasia in the HIV sero-positive females attending the Infectious Disease Clinic at the
Princess Margaret Hospital, Nassau, Bahamas.
Methods: One hundred consecutive, consenting, non-pregnant, HIV-sero-positive females from the Infectious
Disease Clinic at the Princess Margaret Hospital in Nassau, Bahamas were screened for high-risk HPV infections
and cervical cytology abnormalities using liquid-based pap smear and signal amplification nucleic acid method for
HPV detection. A questionnaire was also utilized to gather demographic information and obtain information on
known risk factors associated with HPV infections such numbers of partners.
Results: The prevalence of high-risk HPV was 67% and cervical abnormalities were noted in 44% of the study
population. High-risk HPV types were more likely to be present in women with CD4+ cell counts less than 400
μl-1 and in women with cervical cytology abnormalities (97%). The most common cervical abnormality was low-
grade squamous intraepithelial lesions.
Conclusion: Findings suggest that HIV-sero positive females should have HPV testing done as part of their
normal gynecology evaluation and these patients should be encouraged and provisions be made for ease of access
having regular PAP smears and HPV testing.
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Background
The human papillomavirus (HPV) is the major etiologic
agent in the development of cervical cancer [1] with
known risk factors such an early age at first intercourse,
history of multiple sexual partners, oral contraceptive use,
high parity, lower socioeconomic status, and immuno-
suppression. In immunocompetent subjects, HPV infec-
tions normally clear in six to twenty-four months in 70%
of females [2]. The natural history of HPV infection is
altered in persons infected with the human immunodefi-
ciency virus (HIV) and there is an increased likelihood of
persistent HPV infections in this population [3]. This per-
sistent infection increases their risk of having cervical dys-
plasia and cervical intraepithelial neoplasms (CIN) [3,4].
HIV-positive women especially those with severe immu-
nosuppression are five times more likely than HIV sero-
negative women to have lower genital tract neoplasias
[4,7]. High HPV load in HIV-positive women is associated
with a 10-fold increase risk of CIN in severe immunosup-
pression [5]. Recent studies indicate that plasma HIV RNA
levels and CD4+ cell counts are strong determinants of the
ability to detect HPV suggesting that as the immune sys-
tem weakens, it facilitates reactivation of the HPV thus
helping to explain the increase rates of HPV infection in
women with HIV [6,7]. Additionally, Highly Active Anti-
Retroviral Therapy (HAART) does not seem to impact this
increased rate or persistent of HPV infections in this pop-
ulation [8]. For many years the focus of care for HIV sero-
positive patients in the Bahamas was on immune system
reconstitution using HAART. Patients receiving HAART
die less frequently from opportunistic infections but more
now face morbidity from chronic medical diseases and
other illnesses including malignancies. One such prevent-
able disease is cervical cancer. There is no available data
from the Bahamas or the Caribbean that documents the
prevalence of cervical dysplasia or HPV infections in HIV
sero-positive females.
Study goal
The goal of the study is to determine the prevalence of
high-risk HPV infections and associated cervical abnor-
malities in HIV sero-positive females in the Bahamas.
Methods
Study population
One hundred (100) consecutive, consenting, non-preg-
nant, HIV sero-positive females (18) years or older were
recruited from the Infectious Disease Clinic at the Princess
Margaret Hospital in Nassau, Bahamas. The criteria for eli-
gibility required all of the following: Females 18 years and
older, a positive HIV via ELISA and Western Blot methods
and HIV infectivity via sexual intercourse. All participants
were interviewed, provided informed written consent and
had a liquid based pap smeared performed after receiving
consent. The study received ethical approval from the Eth-
ics Committee of the Public Hospital Authority and the
University of the West Indies – Bahamas Campus.
Sample and data collection
Each participant had a vaginal examination performed by
an Obstetrics and Gynaecology Resident. Cervical samples
were collected using a cytobrush (cytobroom) and stored
in Sure Path vials. A cytotechnologist screened the pre-
pared slides. All positive results and fifteen percent (15%)
of all negatives results were reviewed by a board certified
cytopathologist. The cytology was reported as either nega-
tive, atypical squamous cells of unknown significance
(ASCUS), low-grade squamous intraepithelial lesion
(LGSIL) or high-grade squamous intraepithelial lesion
(HGSIL). Additionally co-infections as well as presence of
HPV changes were noted. The Obstetrics and Gynaecology
Oncologist referred all patients with abnormal cytology
results to Colposcopy Clinic for further evaluation, treat-
ment and follow-up as determined.
Each patient was interviewed and a questionnaire com-
pleted by the interviewer. Information on associated HPV
risk factors such as parity, number of sexual partners, and
birth control method, risky behavior such as drug use, sex
under the influence of drugs and condom usage as well as
demographic were obtained via the questionnaire. The
medical records were reviewed to obtain patient's date of
HIV testing and confirm sero-positivity, most recent
CD4+ lymphocyte counts and viral load, and use of high
active anti-retroviral therapy.
CD4+ and viral load
Samples collected from patients were stained with Flow-
CARE PLG CD4 Reagent. CD4+ lymphocytes counts were
determined by flow cytometry. White blood cell counts
were obtained with a COULTER STKS Instrument. The
values were expressed in terms of percentage (%) of total
lymphocytes and absolute count (cells/μL).
The DNA HIV viral load was tested using a quantiplex
HIV-1 RNA 3.0 Assay. This assay is a nucleic acid hydridi-
zation procedure to directly quantify HIV-1 RNA in
human plasma. The HIV-1 is concentrated from the
plasma by centrifugation then the genomic RRNA is liber-
ated from the virions and captured on a microwell by spe-
cific synthetic oligonucleotide capture probes. The probes
bind to different regions of the pol gene of the viral RNA
which is them amplified.
Multiple copies of the alkaline phosphatase-labelled
probe are then hybridized to an immobilized complex to
amplify the signal. Detection is achieved by incubating
the complex with a chemiluminescent substrate. The light
emission generated by the bound alkaline phosphatase
reacting with the chemiluminescent substrate is recordedInfectious Agents and Cancer 2009, 4(Suppl 1):S8 http://www.infectagentscancer.com/content/4/S1/S8
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as relative light units (RLUs). The light emission is directly
proportional to the amount of HIV-1 present in each sam-
ple. A standard curve is defined by light emission from
standards containing known concentrations of beta
proiolactone (BPL)-treated virus. Concentrations of HIV-
1 RNA in plasma specimens are determined form this
standard curve.
HPV testing
HPV was detected using the HPV Hybrid Capture II assay
which is a signal amplification nucleic acid method for
the qualitative detection of eighteen types of human pap-
illomavirus (HPV) DNA in cervical specimens. The assay
differentiates between high risk and low risk groups. High
HPV types detected are 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59 and 68.
Statistical analysis
Clinical and laboratory risk factors for the study popula-
tion were imported to a statistical software package for
analysis. Statistical analyses were performed using the
Intercooled STATA (version SE 10.0) software (StataCorp.
LP, College Station TX). Factors associated with high-risk
HPV status were selected based on cross-tabulations and
univariate logistic regression analyses. Cross-tabulations
were analyzed using the Fisher's exact test. Logistic regres-
sion was used to perform the analyses of associations
between demographic, behavioral and clinical variables
with high-risk HPV status. Crude odds ratios were first cal-
culated. Potential confounders were identified based on
p-values = 0.05. Logistic regression was used to calculate
the relative odds of high-risk HPV status after adjusting for
the potential confounders (age (continuous), marital sta-
tus, number of pregnancies, Tobacco use, duration of
HAART therapy, CD4 counts, viral load and cervical cytol-
ogy).
Results
Characteristics of the study population
One hundred females ranging from ages 20–71 years were
interviewed and had a PAP smear performed. The mean
and median ages were 40.1 years and 39 years respec-
tively. Fifty-six participants (56%) were single and twenty-
four (24%) were married (Table 1). Ninety-four partici-
pants were Bahamians with only 6% accounting for other
nationalities. Thirty-nine percent reported their age of first
sexual intercourse prior to age 16 years and seventy partic-
ipants (70%) were sexually active before the age of 18
years. Sixty participants (60%) had five or more lifetime
sexual partners.
Sixty-seven women (67%) tested positive for high-risk
HPV genotypes. The proportion of high-risk HPV-positive
women was significantly higher than those who are HPV-
negative (p = 0.001). Forty-four women (44%) were
found to have abnormal cervical cytology with 95% test-
ing positive for high-risk HPV. Seven patients (7%) had
ASCUS, LGSIL in 31 (31%) and HGSIL in six (6%) partic-
ipants.
High-risk HPV infections and behavior
Adjusting for potential confounders (Adjusted Odds Ratio
[AdjOR] 27.0, 95% confidence interval [CI] 2.0–355.3),
one hundred percent of participants with HGSIL were
high-risk HPV positive (Table 2).
There were no statistically significant associations
observed between high-risk HPV infections and alcohol
use, marijuana use, tobacco use or cocaine use. There were
no associations between high-risk HPV infections and
genital herpes, gonorrhea, syphilis, chancroid, trichomo-
niasis or Chlamydia infections, (p > 0.1). Of note, partic-
ipants with greater than ten lifetime sexual partners were
four times more likely to have high-risk HPV infections
than those with less than 10 lifetime sexual partners
(AdjOR 4.4, 95% CI 0.7 – 29.6). This finding was not sta-
tistically significant.
Table 1: Demographics and characteristics of the study 
population
N
Marital Status
Single 56
Married 24
Divorced 9
Widowed 11
Nationality
Bahamians 94
Haitians 4
Jamaicans 2
Alcohol Use
Never 52
Ever 48
Marijuana Use
Never 82
Ever 18
Tobacco Use
Never 89
Ever 11
HAART Therapy
No 18
Yes 81
Cervical Cytology
Negative 56
ASCUS 7
LGSIL 31
HGSIL 6
High Risk HPV
Negative 32
Positive 67
Not available 1
Total 100Infectious Agents and Cancer 2009, 4(Suppl 1):S8 http://www.infectagentscancer.com/content/4/S1/S8
Page 4 of 6
(page number not for citation purposes)
High-risk HPV infection and clinical correlates of HIV 
infection
The mean and median CD4+ lymphocyte counts were
339.15 and 260 respectively. Twenty-three participants
(23%) had CD4+ counts ≥ 500 μl-1, 38 (38%) had CD4+
counts between 200 and 499 μl-1, and 39 (39%) had
CD4+ counts less that 200 μl-1. After adjusting for poten-
tial confounders, subjects with CD4+ counts greater than
400 μl-1 were less likely to test positive for high-risk HPV
(AdjOR 0.2, 95% CI: 0.05 – 0.8, p = 0.019) (Table 3).
Discussion
High-risk HPV is prevalent in the HIV sero-positive
females attending the Infectious Disease Clinic at the
Princess Margaret Hospital. Unfortunately, a comparison
with the HIV sero-negative population could not be done
as there is no published HPV prevalence study for the gen-
eral population. The high prevalence reported in this
study is not unusual with HPV infections being quoted as
anywhere from 33–47% in other published studies [9-
12]. The increased risk of HPV infections in sero-positive
women with multiple partners and early onset of sexual
activities only confirm what multiple studies have dem-
onstrated previously. There is a strong correlation
between the presence of high-risk HPV and cervical cytol-
ogy abnormalities. Forty-one of the forty-four patients
with cervical cytology abnormalities were high-risk HPV
positive demonstrating the role of high-risk HPV in cervi-
cal dysplasia. Participants were not tested for low-risk
HPV genotypes. HIV sero-positive women tend to be
infected with multiple genotypes of HPV [10,11]. Three
participants with cervical abnormalities were not high-
risk HPV positive and may have infections with low risk
HPV genotypes. There is a lack of evidence to suggest that
low-risk HPV genotypes do not play a role in the increase
level of cervical abnormalities and cervical intraepithelial
lesions in this immune-compromised population.
Subjects living with HIV infection for two to six years were
three times more likely to carry high-risk HPV infections
Table 2: Association of high-risk HPV with behavioral variables
High Risk HPV Infections
Negative (32)
N
Positive (67)
N
Odds Ratio
(95% CI)
Adjusted Odds Ratio
(95% CI)*
Age
<40 10 42 1.0 (ref) 1 (ref)
40+ 22 25 0.3 (0.1–0.7) 0.4 (0.1–1.5)
Birth-control method
None 5 7 0.6 (0.1 – 2.3) 0.3 (0.0 – 5.1)
Barrier 10 24 1.0 (ref) 1.0 (ref)
No barrier 2 12 2.5 (0.5–13.3) 6.8 (0.7 – 67.8)
Abstinence 15 24 0.7 (0.3 – 1.8) 0.5 (0.1 – 2.5)
Age at menarche
<13 years 10 22 1.0 (ref) 1.0 (ref)
13+ years 22 45 0.9 (0.4 – 2.3) 2.3 (0.5–9.8)
Number of pregnancies
<3 6 31 1.0 (ref) 1.0 (ref)
3+ 26 36 0.3 (0.1 – 0.7) 0.2 (0.1 – 0.99)
Age of first sexual intercourse
<16 years 12 27 1.0 (ref) 1.0 (ref)
16+ years 20 40 0.9 (0.4 – 2.1) 1.0 (0.3 – 3.8)
Lifetime number of sex partners
<5 11 28 1.0 (ref) 1.0 (ref)
5 to 10 16 24 0.6 (0.2 – 1.5) 1.2 (0.3 – 5.4)
>10 5 15 1.2 (0.3 – 4.0) 4.4 (0.7 – 29.6)
Alcohol
Never 18 34 1.0 (ref) 1.0 (ref)
Ever 14 33 1.3 (0.5 – 2.9) 1.7 (0.4 – 6.8)
Marijuana
Never 27 54 1.0 (ref) 1.0 (ref)
Ever 5 13 1.3 (0.4 – 4.0) 7.0 (0.5 – 91.2)
Tobacco
Never 27 63 1.0 (ref) 1.0 (ref)
Ever 7 4 0.2 (0.1 – 0.8) 0.2 (0.04 – 1.6)
ref = reference; *Adjusted for age (continuous), marital status, number of pregnancies, Tobacco use, duration of HAART therapy, CD4 counts, viral 
load and cervical cytology; Birth control method: Barrier = male condom, No barrier = birth control pill or Depo-Provera®Infectious Agents and Cancer 2009, 4(Suppl 1):S8 http://www.infectagentscancer.com/content/4/S1/S8
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than those infected for less than two years, however this
association was not significant (p > 0.1). Similarly,
women who lived with HIV infections for more than 6
years were almost two times more likely to carry high-risk
HPV infections however; this also was not significant.
Individuals with a CD4+ lymphocyte count of less than
400 μl-1 were more likely to test positive for high-risk HPV
genotypes. As CD4+ count is a reflection of the state of the
immune system, it reasonable to assume that the immune
dysfunction noted at lower CD4+ levels is responsible for
the increased detection of high-risk HPV in these women.
An increased number of lifetime sexual partners was asso-
ciated with an increased likelihood of testing positive for
high-risk HPV. Other behavioral variables such as cocaine
use, alcohol use and non-barrier method did not show the
expected increased risk. This lack of increased risk could
be the result of a relatively small study population.
Conclusion
The high prevalence of high-risk HPV genotypes and cer-
vical cytology abnormalities demonstrates the need to
screen and monitor HIV sero-positive women and to
implement preventative measures to decrease the num-
bers of females with high risk HPV infections. Most partic-
ipants reported not having yearly PAP smears and
unfortunately, routine HPV screening is not conducted at
the public facilities where most of these patients receive
their PAP smears. Screening for HPV infections in HIV
sero-positive females should be an integral component of
their routine gynaecological evaluation and these patients
should be encouraged and provisions be made for ease of
access to having regular PAP smears and HPV testing.
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